Design Therapeutics (DSGN) Research & Development (2020 - 2026)

Design Therapeutics has reported Research & Development for 7 years, with the latest figure at $16.4 million in Q2 2026.

• Research & Development for Q2 2026 came in at $16.4 million, up 4.13% year-over-year; the trailing twelve-month figure through Jun 2026 was -$248000.0 (down 100.45% YoY), and the FY2025 annual result was $100000.0, down 99.77% from the prior year.
• Research & Development improved to $16.4 million in Q2 2026, from $14.4 million in the prior quarter.
• Over five years, Research & Development peaked at $17.1 million in Q2 2023 and troughed at -$45.6 million in Q4 2025.
• A 5-year average of $10.0 million and a median of $13.8 million in 2022 frame the typical range for Research & Development.
• The widest annual swing landed in 2022, when Research & Development jumped 126.04%; it then sank 475.13% in 2025.
• A 5-year view of Research & Development shows it stood at $14.3 million in 2022, then retreated by 22.75% to $11.0 million in 2023, then advanced by 10.4% to $12.2 million in 2024, then sank by 475.13% to -$45.6 million in 2025, then jumped by 135.94% to $16.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $16.4 million in Q2 2026, $14.4 million in Q1 2026, and -$45.6 million in Q4 2025.